KMT2A and acute myeloid leukemia: Revumenib (SNDX-5613) is another oral menin–KMT2A inhibitor and analog of VTP-50469 that exhibits potent preclinical antileukemic activity in KMT2Ar and NPM1-m AML, including long-term remissions after treatment termination [55].